Lab Phone:(773) 702-3992
1999 B.A. Biological Sciences, Molecular and Cellular Biology, Northwestern University
2006 Ph.D., Immunology, The University of Chicago
2007 M.D., The University of Chicago, Pritzker School of Medicine, Chicago
2007-2010 Residency, Clinical Pathology, The University of Chicago
2010-2012 Postdoctoral Research Fellowship, Institute for Genomics and Systems Biology, The University of Chicago
2012-2014 Instructor, Department of Pathology, The University of Chicago, Chicago, IL
2014 Assistant Professor, Department of Pathology and Department of Pediatrics, Section of Hematology-Oncology, The University of Chicago
2014 Attending, Division of Genomic and Molecular Pathology, Department of Pathology, The University of Chicago
Haploinsufficient transcriptional regulators are emerging as a unique class of cancer drivers. For this growing list of transcription factors and chromatin regulators, deletion or mutation of a single allele can promote cancer development. This is a major health issue, as therapeutically targeting this class of cancer drivers is not straight forward. Our lab identified one such transcription factor, CUX1, to be a haploinsufficient tumor suppressor gene that is inactivated in half of high-risk myeloid neoplasms. Others have identified CUX1 inactivating mutations in a wide variety of solid tumors. We are now determining the function of CUX1 through a combination of in vivo mouse models, primary human hematopoietic stem cell and leukemia cell culture, and functional genomic approaches to accomplish the following aims:
1. Identify the role for CUX1, a non-clustered homeobox gene, in cellular growth and differentiation.
2. Determine how CUX1 regulates transcription during normal hematopoiesis and how this program is altered in leukemia.
3. Decipher the cis-regulatory logic of dosage-dependent transcriptional deregulation.
4. Leverage this information to identify and test new therapeutic strategies for myeloid neoplasms.
Our lab is located in the section of Pediatric Hematology/Oncology with a number of other active laboratories addressing related issues. As members of the Hematopoiesis and Hematological Malignancies research program (with over thirty faculty) within the University of Chicago Comprehensive Cancer Center, we regularly interact and collaborate with other laboratories with expertise in basic and translational research. We are currently recruiting passionate and motivated graduate students and post-docs, please contact us if you are interested in joining our group.